Intuitive Surgical stock trades near record territory as robotic surgery demand supports valuation

Intuitive Surgical stock, linked to Intuitive Surgical Inc. (ISIN US46120E6023) and traded on Nasdaq under the symbol ISRG, has been supported by robust growth in robotic-assisted surgery volumes and recurring revenue from instruments and services, as reflected in the company’s latest reported financial results for fiscal 2024 and early 2025 according to investor materials on 16 April 2025.

Revenue up double digits in 2024

According to Intuitive Surgical’s investor relations information for fiscal 2024, the company reported full-year revenue of approximately $7.1 billion, representing year-on-year growth of about 11% compared with around $6.4 billion recorded in 2023, underscoring the continued expansion of its installed base and procedure volumes as highlighted in its annual update.

The same materials indicate that instrument and accessory revenue, which is closely tied to the number of procedures performed on the da Vinci Surgical System, contributed the majority of total revenue in 2024 and continued to grow at a high-single to low-double-digit rate compared with 2023, demonstrating the strength of Intuitive Surgical’s recurring revenue model.

Procedure growth and installed base expansion

Intuitive Surgical’s disclosures for 2024 show that the number of procedures performed using the da Vinci Surgical System grew by roughly 15% compared with the prior year, driven by broader adoption in general surgery, urology, and gynecology, and supported by expansion into additional indications in markets such as the United States, Europe, and Asia.

The company also reported that its global installed base of da Vinci systems increased to more than 8,500 units by the end of 2024, up from roughly 7,200 at the end of 2023, reflecting continued capital placements in hospitals seeking to expand minimally invasive surgery offerings and enhance operating room efficiency.

Da Vinci system drives recurring revenue

Intuitive Surgical’s core product is the da Vinci Surgical System, a robotic-assisted platform that enables minimally invasive surgery through enhanced visualization, precision, and dexterity for surgeons who operate the robotic arms from a console while viewing a magnified three-dimensional image of the surgical field.

The system’s economics rely heavily on recurring revenue from instruments and accessories that must be replaced after a specified number of uses, as well as service contracts for maintenance and support, which together represent a substantial share of Intuitive Surgical’s overall revenue and contribute to relatively stable cash flows despite cyclical variation in capital equipment placements.

Stock valuation supported by growth metrics

As of a recent quote in mid 2025, Intuitive Surgical stock was trading in the low to mid $400 range on Nasdaq, implying a market capitalization in excess of $150 billion based on shares outstanding reported in the company’s filings for 2024 and early 2025.

This valuation reflects a price-to-earnings multiple that is elevated compared with many diversified medical technology peers but is supported by Intuitive Surgical’s high gross margin, which has historically been around 68% to 70%, and operating margin that has trended above 30% in recent years, according to its annual and quarterly reports.

For investors, the combination of double-digit revenue growth, mid-teens procedure expansion, and strong margin profile helps explain why Intuitive Surgical stock trades at a premium multiple, as the market prices in continued adoption of robotic-assisted surgery and the potential for new platforms such as ion for lung biopsy and future innovations in soft tissue surgery.